Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Show more
Location: 4400 Route 9 South, Freehold, NJ, 07728, United States | Website: https://channeltherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
8.904M
52 Wk Range
$0.45 - $3.80
Previous Close
$1.35
Open
$1.40
Volume
291,139
Day Range
$1.25 - $1.53
Enterprise Value
11.28M
Cash
131.3K
Avg Qtr Burn
-1.108M
Insider Ownership
53.88%
Institutional Own.
13.60%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|